In a milestone moment for chronic pain management, Tonix Pharmaceuticals announced on August 15, 2025, that its novel sublingual therapy Tonmya has received approval from the U.S. Food and Drug Administration (FDA) - marking the first new drug for …

… biotechnology company, today announced the U.S. Food and Drug Administration (FDA … Chief Medical Officer of Tonix Pharmaceuticals. … treatment initiation or dosage increases. Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine … clinical trials in …

… accused of providing the drug that killed a … following morning from “mixed drug toxicity,” Carlucci wrote. … order are charges of drug delivery resulting in death … mixed drug toxicity, including cocaine, hydroxyzine, citalopram and cyclobenzaprine. According …

… , clinically meaningful antidepressant effects, which … Tonix Pharmaceuticals announced that Tonmya (cyclobenzaprine HCl … differences. Both medications target VMAT2 … Pharmaceutical has submitted a new drug application to the FDA for centanafadine for treatment …

… a lower dose of cyclobenzaprine than the pill formulations used to … FDA was based on two late-stage studies, in which the drug … a number of already-available treatment options for fibromyalgia, including … cyclobenzaprine, which is due to start a phase 2 trial …

Tonix Pharmaceuticals has launched Tonmya (cyclobenzaprine), a newly approved oral treatment for … patients. Across phase 3 trials, the drug significantly reduced patients’ daily … Anesthesiology, Pain, and Perioperative Medicine at The University of Kansas …

… , a tricyclic antidepressant, is conditionally … Pharmaceuticals Holding Corp) is a new sublingual formulation of cyclobenzaprine … .9  Clinical Trials RELIEF (NCT04172831) … trial.13 Conclusion Sublingual cyclobenzaprine HCl, a recently FDA-approved treatment …

… Drug Administration (FDA) has cleared the Investigational New Drug … (IDA) application for development of TNX-102 SL (cyclobenzaprine hydrochloride) for treatment … chief medical officer of Tonix Pharmaceuticals, … with traditional antidepressants like weight …

… treatment strategies, management of chronic pain, innovations in pharmaceutical … adverse effects, individualized medicinal practices, studies in … struggle to swallow pills. The product … Drugs, Neuromuscular Blocking Agents 2) By Formulation: Cyclobenzaprine, …

… Pharmaceuticals Holding Corp., a fully integrated, commercial biotechnology company, announced that Tonmya (cyclobenzaprine … phase 3 trial, RESILIENT, was published in Pain Medicine with … bedtime treatment for fibromyalgia. Across both phase 3 trials, Tonmya …